Answers are grounded in this paper and cite their sources.
Clear cell renal cell carcinoma (ccRCC) exhibits substantial molecular and immune heterogeneity, yet the role of integrated cell death- and senescence-associated (CDS) programs remains incompletely understood. We characterized 21 CDS transcriptional signatures using multicohort transcriptomic, clinical, pharmacogenomic, and single-cell data. Consensus clustering of 538 TCGA-KIRC tumors identified three subtypes characterized by metabolic–proliferative, immune–inflammatory, and hypoxia–angiogenesis-associated profiles. The immune-enriched C2 subtype showed the poorest survival with elevated exhausted and regulatory T-cell signatures. Focusing on C2, edge perturbation analysis identified 246 network-associated genes, which were narrowed to 23 CDS-related candidates and 12 survival-associated genes. Among 101 machine-learning combinations, CoxBoost followed by random survival forest achieved the best performance, generating a ten-gene prognostic signature with a mean C-index of 0.733 across five cohorts. The resulting risk score was associated with survival outcomes and adverse clinicopathological characteristics. Among the ten genes, LMNB1, LY96, and HSPA8 were further investigated based on their differential expression and high tumor–normal discrimination AUCs. Single-cell profiling and virtual knockout analyses linked LMNB1 to T-cell cytotoxicity-associated networks, LY96 to macrophage antigen-presentation programs, and HSPA8 to T-cell cytokine signaling. Pharmacogenomic analysis identified nine compounds with differential predicted drug responses in C2. Across three independent treatment cohorts, C2 consistently exhibited the lowest response rates. Collectively, these findings demonstrate that integrated CDS transcriptional profiling delineates prognostically distinct molecular states in ccRCC, revealing an immune-enriched yet unfavorable subtype and identifying candidate genes that link cellular stress-associated programs to tumor immune heterogeneity.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: